Steve Vucic1,2, Seward B Rutkove3,4. 1. Sydney Medical School, University of Sydney, Sydney, New South Wales. 2. Department of Neurology, Westmead Hospital, Westmead, New South Wales, Australia. 3. Beth Israel Deaconess Medical Center. 4. Harvard Medical School, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder of the motor neurons, characterized by upper motor neuron (UMN) and lower motor neuron (LMN) dysfunction. There have been significant technological advances in the development of neurophysiological biomarkers of UMN and LMN dysfunction in ALS. In this review, we discuss major advances in development of neurophysiological biomarkers in ALS, critiquing their potential in diagnosis and prognosis of ALS, as well as utility in monitoring treatment effects. RECENT FINDINGS: The threshold tracking transcranial magnetic stimulation (TMS) technique has established cortical hyperexcitability as an early and specific biomarker of UMN dysfunction in ALS, and associated with neurodegeneration. In addition to establishing cortical hyperexcitability as a pathophysiological mechanism, threshold tracking TMS has enabled an earlier diagnosis of ALS and provided a means of monitoring effects of therapeutic agents. Biomarkers of LMN dysfunction, including motor unit number estimation, the neurophysiological index, electrical impedance myography and axonal excitability techniques, have all exhibited utility in monitoring disease progression. SUMMARY: In addition to enhancing ALS diagnosis, the development of novel neurophysiological biomarkers has implications for clinical trials research and drug development, enabling the assessment of biological efficacy of agents in early stages of drug development.
PURPOSE OF REVIEW: Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder of the motor neurons, characterized by upper motor neuron (UMN) and lower motor neuron (LMN) dysfunction. There have been significant technological advances in the development of neurophysiological biomarkers of UMN and LMN dysfunction in ALS. In this review, we discuss major advances in development of neurophysiological biomarkers in ALS, critiquing their potential in diagnosis and prognosis of ALS, as well as utility in monitoring treatment effects. RECENT FINDINGS: The threshold tracking transcranial magnetic stimulation (TMS) technique has established cortical hyperexcitability as an early and specific biomarker of UMN dysfunction in ALS, and associated with neurodegeneration. In addition to establishing cortical hyperexcitability as a pathophysiological mechanism, threshold tracking TMS has enabled an earlier diagnosis of ALS and provided a means of monitoring effects of therapeutic agents. Biomarkers of LMN dysfunction, including motor unit number estimation, the neurophysiological index, electrical impedance myography and axonal excitability techniques, have all exhibited utility in monitoring disease progression. SUMMARY: In addition to enhancing ALS diagnosis, the development of novel neurophysiological biomarkers has implications for clinical trials research and drug development, enabling the assessment of biological efficacy of agents in early stages of drug development.
Authors: Stephen A Goutman; Orla Hardiman; Ammar Al-Chalabi; Adriano Chió; Masha G Savelieff; Matthew C Kiernan; Eva L Feldman Journal: Lancet Neurol Date: 2022-03-22 Impact factor: 59.935
Authors: Didu S T Kariyawasam; Arlene D'Silva; Cindy Lin; Monique M Ryan; Michelle A Farrar Journal: Front Neurol Date: 2019-08-19 Impact factor: 4.003
Authors: Markus E Harrigan; Angela R Filous; Andrew P Tosolini; Renee Morris; Jan M Schwab; W David Arnold Journal: Sci Rep Date: 2019-11-13 Impact factor: 4.379
Authors: James A Bashford; Aidan Wickham; Raquel Iniesta; Emmanuel M Drakakis; Martyn G Boutelle; Kerry R Mills; Chris E Shaw Journal: Brain Commun Date: 2020-02-20
Authors: David Czell; Christoph Neuwirth; Markus Weber; Sabine Sartoretti-Schefer; Andreas Gutzeit; Carolin Reischauer Journal: Neurol Res Int Date: 2019-11-07